adminRemedy Q2 2026 revenue declined as the company stepped up marketing for Control Resonant ahead of its September 24 launch. The developer also reported lower first-half revenue and an operating loss, while noting positive early pre-order indicators for the upcoming game.
Image credit: Remedy Entertainment
Remedy Q2 2026 revenue and operating results
For the second quarter of 2026, Remedy recorded revenue of €10.2 million, a 40% decrease. Its operating loss was €3.9 million, compared with a €0.5 million loss in the same quarter a year earlier.
Across the first half of 2026, revenue reached €23.3 million, down 23.1%. The company reported an operating loss of €2.9 million, compared with an operating profit of €0.8 million in 2023.
- Q2 revenue: €10.2 million, down 40%.
- Q2 operating result: €3.9 million loss, versus a €0.5 million loss in the prior-year quarter.
- H1 revenue: €23.3 million, down 23.1%.
- H1 operating result: €2.9 million loss, compared with €0.8 million profit in 2023.
Remedy linked the revenue movement to the timing of FBC: Firebreak in the comparison period and higher marketing activity for Control Resonant. When comparing periods, readers should keep these factors in mind: reported revenue can reflect the timing of game releases, royalties and development work, as well as sales of individual titles.
Control Resonant pre-orders and launch outlook
Remedy said pre-orders for Control Resonant began with healthy momentum. The game ranked among the three most pre-ordered PlayStation titles in the US, Germany and Brazil. CEO Jean-Charles Gaudechon said the company’s internal data showed the title tracking well against comparable releases in its launch window.
Gaudechon also pointed to the game’s distinctive qualities and a slightly less crowded release period than when it was first announced. These are the company’s early indicators, rather than a guarantee of launch sales. The game is scheduled to arrive on September 24, while Remedy plans to increase marketing activity further in the third quarter.
Sales from Remedy’s existing games and projects
Revenue from game sales and royalties was €3.8 million, compared with €9.5 million in the same period last year. The earlier period included contributions from FBC: Firebreak and initial accruals from subscription services.
Sales of 2019’s Control rose in Q2, with ongoing promotion for Control Resonant supporting interest in the earlier game. Alan Wake 2 passed three million lifetime sales. Royalties from that title and Alan Wake Remastered came solely from consumer sales, with no platform deal accruals reported.
Development fees from Control Resonant and the Max Payne 1 & 2 remake totaled €6.4 million, down from €7.4 million in the previous period. Remedy said its existing catalogue continued to provide support while development on its other projects progressed according to plan, including a new project moving toward production readiness.
What the results indicate
The figures show a weaker revenue and operating result for the reported periods, alongside encouraging early pre-order rankings for Remedy’s next major release. Pre-orders and catalogue sales offer useful context, but the company’s performance after launch will depend on results once the game is available.
For readers following Remedy Q2 2026 revenue, the key points are the 40% quarterly decline, the 23.1% first-half decrease and the upcoming Control Resonant launch. Remedy says its focus remains on delivering the game, with further marketing planned in Q3.
